Previous Article | Next Article ![]()
Infection and Immunity, August 2001, p. 5115-5120, Vol. 69, No. 8
Laboratory of Cell Regulation and
Carcinogenesis,1 Immunocompromised Host
Section, Pediatric Oncology Branch,2 and
Advanced Technology Center,3 National
Cancer Institute, National Institutes of Health, Bethesda, Maryland
20892
Received 30 November 2000/Returned for modification 6 February
2001/Accepted 17 April 2001
Candida albicans is an opportunistic fungal pathogen
and a major cause of morbidity and mortality in patients with
compromised immune function. The cytokine response to tissue invasion
by C. albicans can influence the differentiation and
function of lymphocytes and other mononuclear cells that are critical
components of the host response. While the production of transforming
growth factor Chronic disseminated candidiasis
(CDC) is a serious infectious complication that occurs in patients
suffering prolonged periods of neutropenia (25).
Successful treatment of CDC typically requires protracted courses of
antifungal therapy (56). Parenchymal lesions within the
liver in which yeast and pseudohyphae can be found become apparent
during recovery from neutropenia and can progress in size, often with a
strong local inflammatory response. This observation suggests that
inhibitory factors produced locally in response to fungal infection
could impair an effective immune response and consequently, as
circulating neutrophils and monocytes recover, contribute to the
pathogenesis and prognosis of CDC. Several aspects of the host response
to Candida albicans have been defined through studies of
humans with CDC and animal models of disseminated infection. A suitable
animal model for C. albicans infection of the liver in
neutropenic rabbits provides an excellent opportunity to investigate
the pathophysiological model and to develop new therapeutic strategies
(54, 55).
An effective phagocytic response absolutely depends on a balance
between pro-and anti-inflammatory cytokines and on T-helper cells.
Studies of animals models of C. albicans infection have illustrated the protective role of T-helper lymphocyte type 1 (Th1)
cytokines and the suppressive effect of Th2 cytokines on the host
response to infection (34, 42). For example,
interleukin-12 (IL-12) is required for Th1 differentiation in murine
candidiasis (40), and production of this cytokine by
neutrophils correlates with a protective response (41).
Exogenous IL-12 is effective in protecting neutropenic hosts
susceptible to infection and can enhance the host phagocytic response
to C. albicans (41). The role of Th2 cytokines
is less clearly defined, but current data suggest that they impair the
host response to C. albicans (10, 29, 35, 49).
Measurement of high circulating levels of IL-10 in patients with CDC
(38) indicates a shift toward the Th2 response. IL-10 is a
potent inhibitor of cytokine synthesis in human monocytes (15) and can inhibit the release of proinflammatory
cytokines, such as IL-1 and tumor necrosis factor alpha (8,
9). IL-10 inhibits the phagocytic activity of human neutrophils
(7) and suppresses antifungal activities of human
monocytes against the pseudohyphae and blastoconidida of C. albicans (36).
Transforming growth factor Although these studies have shown that systemic administration of a
neutralizing anti-TGF- Human liver biopsy specimens.
Seven patients with
biopsy-documented CDC were identified, and 5-µm sections were
prepared from archival specimens that had previously been fixed in
formalin and embedded in paraffin. Specimens were processed for
immunohistochemical analysis of TGF- Rabbit model of CDC.
New Zealand White rabbits (weight, 2.5 to 3.5 kg; Hazleton, Denver, Pa.) were used for all experiments and
were given water and standard rabbit feed ad libitum according to
National Institutes of Health guidelines (12). The
immunosuppressive regimen and supportive care measures were as
previously described (54, 55). Briefly, cytosine
arabinoside (Upjohn Pharmaceuticals, Kalamazoo, Mich.) was administered
intravenously at 440 mg/m2 on days 1 through 5 and on days
8 to 9 and days 13 to 14 to produce profound and persistent
neutropenia, respectively, and starting on day 4, rabbits received
intravenous administration of ceftazidime (Glaxo Pharmaceuticals,
Research Triangle Park, N.C.) at 75 mg/kg, twice daily, gentamicin
(Baxter Health Care Corp., Deerfield, Ill.) at 5 mg/kg every other day,
and vancomycin (Eli Lilly & Co., Indianapolis, Ind.) intravenously at
15 mg/kg daily to prevent the occurrence of invasive bacterial
infections during neutropenia. An inoculum of 103 CFU of
C. albicans was administered on day 6 as previously
described (22).
Immunohistochemical detection of TGF- Monocyte infection and preparation of conditioned media.
Peripheral blood monocytes were isolated by a two-step procedure,
automated leukopheresis followed by counterflow elutriation (model J-6M
centrifuge; Beckman Instruments, Fullerton, Calif.) (53).
Cell viability was determined to be >95% by trypan blue exclusion.
Morphological analysis by using modified Wright-Giemsa stain and
nonspecific esterase stain confirmed that >95% of the isolated cells
were monocytes. In preparation for ex vivo studies, monocytes were
washed twice in RPMI without fetal calf serum and kept on ice
throughout preparation. The monocytes were resuspended in RPMI at
106/ml in a total volume of 30 ml, immediately placed in a
5% CO2 water incubator, and subjected to either C. albicans strain 86-21 challenge or a sterile-water control
treatment. The C. albicans strain is a clinical specimen and
has been previously studied (37). Monocyte suspensions
were challenged with C. albicans at a multiplicity of
infection (MOI [target-to-effector cells]) of 10:1, 1:1, and 1:10 in
duplicate. Supernatants were collected at 8, 12, 24, and 48 h
after initial infection. The viability of cells was assessed by trypan
blue stain exclusion. For the time points collected, the viability of
monocytes exposed to an MOI of 10:1 was less than 50%. For the other
conditions, the viability was >95% at the time of collection.
Supernatants were collected and frozen at TGF- TGF- Production of TGF-
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.8.5115-5120.2001
Invasive Candidiasis Stimulates Hepatocyte and
Monocyte Production of Active Transforming Growth Factor
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
(TGF-
) has been documented in mice infected with
C. albicans and is known to suppress phagocyte function,
the cellular source and role of this cytokine in the pathogenesis of
systemic candidiasis are not well understood. We have investigated the
source of production of TGF-
by immunohistochemical studies in
tissue samples from patients with an uncommon complication of
lymphoreticular malignancy, chronic disseminated candidiasis (CDC), and
from a neutropenic-rabbit model of CDC. Liver biopsy specimens from
patients with documented CDC demonstrated intense staining for
extracellular matrix-associated TGF-
1 within inflammatory
granulomas, as well as staining for TGF-
1 and TGF-
3 within
adjacent hepatocytes. These results correlate with the
immunolocalization of TGF-
observed in livers of infected neutropenic rabbits, using a neutralizing antibody that recognizes the
mature TGF-
protein. Human peripheral blood monocytes incubated with
C. albicans in vitro release large amounts of biologically active TGF-
1. The data demonstrate that local production of active TGF-
s by hepatocytes and by infected mononuclear cells is a
component of the response to C. albicans infection that
most probably contributes to disease progression in the
immunocompromised host.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
(TGF-
) is another important
inhibitory cytokine (5, 27), but the role that it plays
during infection with C. albicans is not clearly defined.
Release of TGF-
down-regulates activated monocytes and macrophages,
suppressing gamma interferon (IFN-
)-induced production of nitric
oxide (51), which would favor the dissemination and
progression of C. albicans infection. TGF-
is generally
thought to influence the differentiation of naive CD4+T
cells toward the Th2 profile (27), although it has been
shown to inhibit Th2 differentiation (21). Murine models
characterized by disruptions in the TGF-
pathway are notable for a
proinflammatory phenotype, with spontaneous differentiation and
activation of T cells producing IFN-
and IL-4 (20, 26,
46). Studies with mice have suggested a role for TGF-
in
determining the response to C. albicans (48),
by demonstrating that production of TGF-
quickly follows infection
with a nonvirulent vaccine strain of C. albicans, and have
shown that this role might be important in the development of
resistance. However, the observation that administration of exogenous
TGF-
could promote the development of a Th1 response in these mice
highlights the complex local effects of this cytokine and suggests that
TGF-
might play a critical regulatory role in the host response to
C. albicans infection (48).
antibody can affect the course of C. albicans infection in mice, the cellular source and local production of TGF-
have not been clearly determined. The objective of this study was to demonstrate that local production of TGF-
accompanies the granulomatous response to tissue invasion in CDC and to
investigate whether human monocytes challenged by C. albicans produce biologically active TGF-
. The results suggest
an important role for TGF-
in the pathophysiology of CDC.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
as described below.
isoforms in human and
rabbit tissues.
Sections 5 µm thick were stained with
hematoxylin and eosin for routine histological evaluation. Additional
sections were evaluated with isoform-specific anti-TGF-
antibodies
directed against TGF-
1 (18), TGF-
2
(16), and TGF-
3 (17), followed by
peroxidase staining as previously described (18). The
sections were also evaluated using a biotinylated mouse monoclonal
antibody that was raised against mature, active TGF-
2 but can
recognize and neutralize the activity of all three isoforms (clone
1D11; Genzyme, Cambridge, Mass., and now available through R&D Systems, Minneapolis, Minn.).
70°C until analysis.
bioassay.
A modified Mv1Lu bioassay was used
(13). Cells were plated at 2 × 105 cells
per well in 24-well plates with 1 ml of Dulbecco's modified Eagle's
medium containing 10% fetal bovine serum and incubated for 8 to
12 h at 37°C to ensure complete adherence. The medium was
aspirated and replaced with serial dilutions of each conditioned medium
(diluted in Dulbecco's modified Eagle's medium containing 0.2% fetal
bovine serum) in the presence or absence of 30 µg of either the
panspecific mouse monoclonal anti-TGF-
blocking antibody 1D11 or
control IgG per ml; additional wells were treated with medium plus
TGF-
standard concentrations in a total volume of 500 µl/well
(each condition was tested in triplicate). The plates were subsequently
incubated for an additional 24 h, and 1 mCi of
[3H]thymidine was added for the final 2 h of the
incubation. The medium was aspirated and replaced with 50 µl of
trypsin-EDTA/well, and the cells were incubated for 30 min at 37°C
before being harvested onto 24-well filter plates, which were processed
with a Top Count microplate scintillation reader as specified by the
manufacturer (Packard Instrument Co., Meriden, Conn.).
SELISA.
Culture supernatants were collected as above
for determination of total TGF-
by the Quantikine SELISA (R&D
Systems). Total TGF-
was measured after acidification to activate
latent TGF-
followed by neutralization specified by the
manufacturer, with standard curves for TGF-
generated with known
amounts of purified recombinant human TGF-
1.
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
accompanies the local inflammatory response
to C. albicans in vivo.
We examined the expression of
TGF-
within the inflammatory liver granulomas of seven patients with
documented CDC. Immunohistochemical studies demonstrated intense
staining for TGF-
1 within the extracellular matrix surrounding
infiltrates of leukocytes within the liver parenchyma (Fig. 1A to
D) and revealed an extensive accumulation of TGF-
protein encasing necrotic foci that resulted from the intense local inflammatory reaction (Fig. 1E).

View larger version (129K):
[in a new window]
FIG. 1.
Immunolocalization of TGF-
1 within the extracellular
matrix of hepatic granulomas of patients with CDC. Tissue sections from
seven patients with CDC were examined by immunohistochemistry with a
polyclonal rabbit antibody (designated CC) that detects extracellular,
matrix-associated TGF-
1. Sections stained with normal rabbit serum
(A) or the CC antibody (B to E) are shown.
isoforms in areas adjacent to the inflammatory reaction. There was
strong cytoplasmic localization of both TGF-
3 (Fig. 2B), and TGF-
1 (Fig. 2C and D) to
hepatocytes in all biopsy specimens, with the predominant expression
centered around sites of inflammation. We subsequently evaluated
whether this local expression of TGF-
detected in livers of
immunocompromised patients might also be a feature of the invasive
lesions observed in the neutropenic-rabbit model of CDC. Similar to the
findings in human liver biopsy specimens, an accumulation of
extracellular TGF-
1 was evident in rabbit liver sections that were
stained with an antibody reactive to matrix-associated forms of the
mature protein (Fig. 3A to D). We also
used a biotinylated anti-TGF-
mouse IgG that is not isoform specific
but does recognize the mature, active forms of TGF-
. Once again, we
observed intense cytoplasmic staining for TGF-
within hepatocytes in
regions of the liver where inflammation was most abundant (Fig. 3E and
F).
|
|
Monocyte infection by C. albicans results in the
secretion of biologically active TGF-
.
Infiltrating leukocytes
might also contribute to the local production of TGF-
in the liver
following infection with C. albicans. To study this
possibility, monocytes were isolated by leukapheresis and counterflow
elutriation and cultured at specified ratios of blastoconidia to
monocytes in serum-free medium. Culture supernatants were then
collected at time intervals ranging from 8 to 48 h, and the
presence of biologically active TGF-
was determined by the ability
to inhibit growth of a TGF-
-sensitive mink lung epithelial cell line
in a manner reversible with a neutralizing. TGF-
-specific antibody.
Supernatants from cultures of 1.5 × 106/ml monocytes
at a blastoconidia-to-monocyte ratio of 1:1 contained more than 1 ng of
biologically active TGF-
per ml. As shown in Fig.
4, substantial amounts of TGF-
could
be detected as early as 12 h, and similar results were obtained in
assays of supernatants collected at later time points. A determination
of total TGF-
was performed on the same culture supernatants
following a transient acidification to release any mature TGF-
remaining associated with the latency-associated protein. The results
shown in Fig. 5 directly correlate with
values determined by the bioassay and suggest that the majority of the
TGF-
released into the medium by infected monocytes is biologically
active.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
Our results demonstrate that active TGF-
is produced by
hepatocytes and infiltrating monocytes within inflammatory granulomas during CDC. Furthermore, we show an induction of active TGF-
in
hepatocytes and an accumulation of extracellular, matrix-associated TGF-
in areas surrounding both inflammatory granulomas and the residual necrotic foci that are characteristic of CDC. We present evidence that local production of TGF-
is not unique to CDC in humans but that it also occurs during C. albicans infection
in immunocompromised rabbits following prolonged periods of
neutropenia. Infection of monocytes with C. albicans leads
to the secretion of active TGF-
, clearly implicating leukocytes as
an additional source of this cytokine in CDC. Since clinical expression
of CDC is often accelerated during and after recovery from neutropenia and monocytopenia, we infer that the high local concentration of
TGF-
participates in the suppression of host defenses.
Previously, it has been shown that the immunoregulatory properties of
TGF-
affect the differentiation and function of nearly every
leukocyte subset (27). TGF-
primarily inhibits the
differentiated function of immune cells (i.e., phagocytes), although
several studies suggest that it can also enhance the function of
lymphocytes and macrophages. For example, femtomolar concentrations of
TGF-
are chemotactic for human peripheral blood monocytes and
neutrophils, suggesting a critical role in recruitment to sites of
injury or inflammation. Mice lacking the MADH3 gene,
encoding the TGF-
receptor-activated Smad3, have defective
chemotactic responses to TGF-
in neutrophils, monocytes, and
keratinocytes; they spontaneously develop mucosal abscesses with
nonpathogenic Providencia spp. (14, 59).
TGF-
can also contribute to the formation of inflammatory foci by
enhancing the expression of several integrin receptors on monocytes,
namely, LFA-1, VLA-3, and VLA-5 (3, 52). TGF-
enhances
phagocytosis by induction of the expression of Fc
RIII receptors on
circulating monocytes (57). These data suggest that local
production of TGF-
within tissues may promote the infiltration of
mononuclear cells responding to pathogens such as C. albicans.
On the other hand, TGF-
is also known to inhibit the function of
immune cells (i.e., lymphocytes and phagocytes) postactivation. For
example, TGF-
is a potent inhibitor of the production of reactive
oxygen radicals and nitrogen intermediates by cells activated by either
IFN-
or bacterial lipopolysaccharide. (6, 51). Interestingly these activating signals are also recognized for their
ability to induce monocytes and macrophages to release TGF-
in an
active state, through mechanisms that involve the serine protease
plasmin and tissue type II transglutaminase (32, 33). C. albicans infection of IFN-
and
lipopolysaccharide-activated murine peritoneal macrophages can also
suppress the production of nitric oxide, although this effect has been
described as being independent of induction by TGF-
, primarily
because it was not neutralized by a blocking antibody to TGF-
(11). While this autocrine activity generally is believed
to function as an important feedback-inhibitory mechanism for limiting
the extent and duration of an inflammatory response, it is also well
recognized as a microbial escape mechanism in human and murine forms of
parasitic infection. Indeed, infection of host macrophages with either
Leishmania or the protozoan parasite Trypanosoma
cruzi results in the secretion of the mature, active TGF-
that
suppresses microbicidal activity against the parasite and thereby
enhances the proliferation of the pathogen (1, 2, 30, 47).
The effects of TGF-
on the development of host defense pathways have
also been studied during infection with Mycobacterium
tuberculosis and leprosy. TGF-
is produced by M. tuberculosis-infected macrophages (39), and
neutralization of TGF-
normalizes lymphocyte proliferative responses
to the standard purified protein derivative; partially restores
blastogenesis to candidal antigen, and increases IFN-
production,
indicating that TGF-
is an important mediator of immunosuppression
in tuberculosis (23, 24). In leprosy, two different
patterns of TGF-
isoform expression are seen in the polar forms of
leprosy in skin biopsy specimens; in the paucibacillary form,
expression of the latent form of TGF-
1 was detected, whereas in the
tuberculoid form, high levels of the active isoforms were detected
(58). Our data provide preliminary evidence that C. albicans could utilize a comparable strategy in the neutropenic host, similar to the observed response to M. tuberculosis
and selected parasitic infections. In our CDC study, the active isoform of TGF-
1 is highly expressed and could be a contributing factor to
CDC pathogenesis.
Another important component of the host response to C. albicans is the development of an effective Th1 response. The
contribution of TGF-
to Th cell differentiation is complex, but
early studies suggested that TGF-
promotes the differentiation of
staphylococcal enterotoxin B-stimulated CD4+ T cells toward
the Th1 phenotype (31). Conversely, others have demonstrated that TGF-
inhibits IL-12-induced Th1 development and
IFN-
production (44, 45). More recent studies involving polyclonal activation of naîve CD4+ T cells and
ovalbumin-specific Th cells have demonstrated that a mixture of IL-4
and TGF-
can promote the development of either Th1 or Th2 cells in a
concentration dependent manner (28). However, the
induction of a Th1 phenotype was dependent on the presence of IFN-
,
which has recently been shown to block TGF-
receptor-mediated signaling though the induction of the inhibitory Smad7
(50).
The establishment of an effective Th1 response in mice with systemic
candidiasis is thought to be dependent on several factors, including
the production of IL-12 (43) and the early presence of
IL-4, which can prime neutrophils for production of IL-12
(29). Studies with mice have shown that IFN-
is
required for an effective Th1 response to C. albicans but
also suggest that presence of TGF-
could favor a Th1 response
(48). Taken together, these observations suggest that
multiple pathways contribute to the differentiation of naîve T
cells and that the intracellular cross talk between pathways, including
TGF-
and Th1 cytokines (4, 50, 60), could unfavorably
tip the balance of the host immune response in the neutropenic host.
The current data collectively demonstrate that TGF-
is an important
determinant of the host response to systemic candidiasis. As a
consequence of the suppressive effects of TGF-
on the phagocytic response, the production of active TGF-
in immunocompromised patients and rabbits with CDC is an important local event, inhibiting effective cell-mediated immunity while permitting ineffective granuloma
formation in response to C. albicans infection. One must
therefore consider the complex role of this molecule and, specifically,
a role for the beneficial effects of TGF-
on Th-cell differentiation. Finally, our study provides evidence that TGF-
production is at least a consequence of C. albicans
infection and, indeed, could be a contributing factor to an unusual
type of infection in the severely immunocompromised host. Other
factors, such as host genetic profiles and prior immunosuppression,
certainly have to be considered in a comprehensive understanding of the pathophysiology of CDC (19).
| |
ACKNOWLEDGMENTS |
|---|
We thank Anita Roberts for critical review of the manuscript.
T.L. was supported by a Mildred Scheel Stipendium, Deutsche Krebshilfe e.V.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Immunocompromised Host Section, Pediatric Oncology Branch and The Advanced Technology Center, National Cancer Institute, 8717 Grovemont Circle, Gaithersburg, MD 20877. Phone: (301) 435-7559. Fax: (301) 402-3134. E-mail: sc83a{at}nih.gov.
Editor: T. R. Kozel
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Barral, A.,
M. Barral-Netto,
E. C. Yong,
C. E. Brownell,
D. R. Twardzik, and S. G. Reed.
1993.
Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis.
Proc. Natl. Acad. Sci. USA
90:3442-3446 |
| 2. |
Barral-Netto, M.,
A. Barral,
C. E. Brownell,
Y. A. Skeiky,
L. R. Ellingsworth,
D. R. Twardzik, and S. G. Reed.
1992.
Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism.
Science
257:545-548 |
| 3. | Bauvois, B., D. Rouillard, J. Sanceau, and J. Wietzerbin. 1992. IFN-gamma and transforming growth factor-beta 1 differently regulate fibronectin and laminin receptors of human differentiating monocytic cells. J. Immunol. 148:3912-3919[Abstract]. |
| 4. |
Bitzer, M.,
G. von Gersdorff,
D. Liang,
A. Dominguez-Rosales,
A. A. Beg,
M. Rojkind, and E. P. Bottinger.
2000.
A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA.
Genes Dev.
14:187-197 |
| 5. |
Blobe, G. C.,
W. P. Schiemann, and H. F. Lodish.
2000.
Role of transforming growth factor beta in human disease.
N. Engl. J. Med.
342:1350-1358 |
| 6. | Bogdan, C., and C. Nathan. 1993. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann. N. Y. Acad. Sci. 685:713-739[Abstract]. |
| 7. | Cassatella, M. A. 1998. The neutrophil: one of the cellular targets of interleukin-10. Int. J. Clin. Lab. Res. 28:148-161[CrossRef][Medline]. |
| 8. |
Cassatella, M. A.,
L. Meda,
S. Bonora,
M. Ceska, and G. Constantin.
1993.
Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide.
J. Exp. Med.
178:2207-2211 |
| 9. |
Cassatella, M. A.,
L. Meda,
S. Gasperini,
F. Calzetti, and S. Bonora.
1994.
Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation.
J. Exp. Med.
179:1695-1699 |
| 10. | Cenci, E., L. Romani, A. Mencacci, R. Spaccapelo, E. Schiaffella, P. Puccetti, and F. Bistoni. 1993. Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur. J. Immunol. 23:1034-1038[Medline]. |
| 11. | Chinen, T., M. H. Qureshi, Y. Koguchi, and K. Kawakami. 1999. Candida albicans suppresses nitric oxide (NO) production by interferon-gamma (IFN-gamma) and lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages. Clin. Exp. Immunol. 115:491-497[CrossRef][Medline]. |
| 12. | Committe on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission on Life Sciences National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C. |
| 13. | Danielpour, D., L. L. Dart, K. C. Flanders, A. B. Roberts, and M. B. Sporn. 1989. Immunodetection and quantitation of the two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) secreted by cells in culture. J. Cell. Physiol. 138:79-86[CrossRef][Medline]. |
| 14. |
Datto, M. B.,
J. P. Frederick,
L. Pan,
A. J. Borton,
Y. Zhuang, and X. F. Wang.
1999.
Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction.
Mol. Cell. Biol.
19:2495-2504 |
| 15. |
De Waal Malefyt, R.,
M., J. Abrams,
B. Bennett,
C. G. Figdor, and J. E. de Vries.
1991.
Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.
J. Exp. Med.
174:1209-1220 |
| 16. | Flanders, K. C., D. S. Cissel, L. T. Mullen, D. Danielpour, M. B. Sporn, and A. B. Roberts. 1990. Antibodies to transforming growth factor-beta 2 peptides: specific detection of TGF-beta 2 in immunoassays. Growth Factors 3:45-52[Medline]. |
| 17. | Flanders, K. C., G. Ludecke, S. Engels, D. S. Cissel, A. B. Roberts, P. Kondaiah, R. Lafyatis, M. B. Sporn, and K. Unsicker. 1991. Localization and actions of transforming growth factor-beta s in the embryonic nervous system. Development 113:183-191[Abstract]. |
| 18. |
Flanders, K. C.,
N. L. Thompson,
D. S. Cissel,
E. Van Obberghen-Schilling,
C. C. Baker,
M. E. Kass,
L. R. Ellingsworth,
A. B. Roberts, and M. B. Sporn.
1989.
Transforming growth factor-beta 1: histochemical localization with antibodies to different epitopes.
J. Cell Biol.
108:653-660 |
| 19. | Foster, C. B., and S. J. Chanock. 2000. Mining variations in genes of innate and phagocytic immunity: current status and future prospects. Curr. Opin. Hematol. 7:9-15[CrossRef][Medline]. |
| 20. | Gorelik, L., and R. A. Flavell. 2000. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12:171-181[CrossRef][Medline]. |
| 21. |
Gorelik, L.,
P. E. Fields, and R. A. Flavell.
2000.
Cutting edge: TGF- inhibits Th type 2 development through inhibition of GATA-3 expression.
J. Immunol.
165:4773-4777 |
| 22. |
Groll, A. H.,
V. Petraitis,
R. Petraitiene,
A. Field-Ridley,
M. Calendario,
J. Bacher,
S. C. Piscitelli, and T. J. Walsh.
1999.
Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits.
Antimicrob. Agents Chemother.
43:2463-2467 |
| 23. |
Hirsch, C. S.,
J. J. Ellner,
R. Blinkhorn, and Z. Toossi.
1997.
In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta.
Proc. Natl. Acad. Sci. USA
94:3926-3931 |
| 24. |
Hirsch, C. S.,
R. Hussain,
Z. Toossi,
G. Dawood,
F. Shahid, and J. J. Ellner.
1996.
Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production.
Proc. Natl. Acad. Sci. USA
93:3193-3198 |
| 25. | Kontoyiannis, D. P., M. A. Luna, B. I. Samuels, and G. P. Bodey. 2000. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect. Dis. Clin. North Am. 14:721-739[CrossRef][Medline]. |
| 26. |
Kulkarni, A. B.,
C. G. Huh,
D. Becker,
A. Geiser,
M. Lyght,
K. C. Flanders,
A. B. Roberts,
M. B. Sporn,
J. M. Ward, and S. Karlsson.
1993.
Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death.
Proc. Natl. Acad. Sci. USA
90:770-774 |
| 27. | Letterio, J. J., and A. B. Roberts. 1998. Regulation of immune responses by TGF-beta. Annu. Rev. Immunol. 16:137-161[CrossRef][Medline]. |
| 28. |
Lingnau, K.,
P. Hoehn,
S. Kerdine,
S. Koelsch,
C. Neudoerfl,
N. Palm,
E. Ruede, and E. Schmitt.
1998.
IL-4 in combination with TGF-beta favors an alternative pathway of Th1 development independent of IL-12.
J. Immunol.
161:4709-4718 |
| 29. |
Mencacci, A.,
G. Del Sero,
E. Cenci,
C. F. d'Ostiani,
A. Bacci,
C. Montagnoli,
M. Kopf, and L. Romani.
1998.
Endogenous interleukin 4 is required for development of protective CD4+ T helper type 1 cell responses to Candida albicans.
J. Exp. Med.
187:307-317 |
| 30. | Ming, M., M. E. Ewen, and M. E. Pereira. 1995. Trypanosome invasion of mammalian cells requires activation of the TGF beta signaling pathway. Cell 82:287-296[CrossRef][Medline]. |
| 31. | Nagelkerken, L., K. J. Gollob, M. Tielemans, and R. L. Coffman. 1993. Role of transforming growth factor-beta in the preferential induction of T helper cells of type 1 by staphylococcal enterotoxin B. Eur. J. Immunol. 23:2306-2310[Medline]. |
| 32. | Nunes, I., J. S. Munger, J. G. Harpel, Y. Nagano, R. L. Shapiro, P. E. Gleizes, and D. B. Rifkin. 1996. Structure and activation of the large latent transforming growth factor-beta complex. Int. J. Obes. Relat. Metab. Disord. 20(Suppl. 3):S4-S8. |
| 33. | Nunes, I., R. L. Shapiro, and D. B. Rifkin. 1995. Characterization of latent TGF-beta activation by murine peritoneal macrophages. J. Immunol. 155:1450-1459[Abstract]. |
| 34. | Puccetti, P., L. Romani, and F. Bistoni. 1995. A TH1-TH2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol. 3:237-240[CrossRef][Medline]. |
| 35. | Puccetti, P., A. Mencacci, E. Cenci, R. Spaccapelo, P. Mosci, K. H. Enssle, L. Romani, and F. Bistoni. 1994. Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J. Infect. Dis. 169:1325[Medline]. |
| 36. | Roilides, E., A. Anastasiou-Katsiardani, A. Dimitriadou-Georgiadou, I. Kadiltsoglou, S. Tsaparidou, C. Panteliadis, and T. J. Walsh. 1998. Suppressive effects of interleukin-10 on human mononuclear phagocyte function against Candida albicans and Staphylococcus aureus. J. Infect. Dis. 178:1734-1742[CrossRef][Medline]. |
| 37. | Roilides, E., C. A. Lyman, S. D. Mertins, D. J. Cole, D. Venzon, P. A. Pizzo, S. J. Chanock, and T. J. Walsh. 1996. Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens. Cytokine 8:42-48[CrossRef][Medline]. |
| 38. | Roilides, E., T. Sein, R. Schaufele, S. J. Chanock, and T. J. Walsh. 1998. Increased serum concentrations of interleukin-10 in patients with hepatosplenic candidiasis. J. Infect. Dis. 178:589-592[Medline]. |
| 39. |
Rojas, R. E.,
K. N. Balaji,
A. Subramanian, and W. H. Boom.
1999.
Regulation of human CD4(+) alphabeta T-cell-receptor-positive [TCR(+)] and gamma delta TCR(+) T-cell responses to mycobacterium tuberculosis by interleukin-10 and transforming growth factor .
Infect. Immun.
67:6461-6472 |
| 40. | Romani, L., F. Bistoni, A. Mencacci, E. Cenci, R. Spaccapelo, and P. Puccetti. 1995. IL12 in Candida albicans infections. Res. Immunol. 146:532-538[CrossRef][Medline]. |
| 41. | Romani, L., F. Bistoni, and P. Puccetti. 1997. Initiation of T-helper cell immunity to Candida albicans by IL-12: the role of neutrophils. Chem. Immunol. 68:110-135[Medline]. |
| 42. | Romani, L., E. Cenci, A. Menacci, F. Bistoni, and P. Puccetti. 1995. T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design. Immunol. Res. 14:148-162[Medline]. |
| 43. | Romani, L., A. Mencacci, L. Tonnetti, R. Spaccapelo, E. Cenci, S. Wolf, P. Puccetti, and F. Bistoni. 1994. Interleukin-12 but not interferon-gamma production correlates with induction of T helper type-1 phenotype in murine candidiasis. Eur. J. Immunol. 24:909-915[Medline]. |
| 44. | Schmitt, E., P. Hoehn, C. Huels, S. Goedert, N. Palm, E. Rude, and T. Germann. 1994. T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur. J. Immunol. 24:793-798[Medline]. |
| 45. | Schmitt, E., E. Rude, and T. Germann. 1997. The immunostimulatory function of IL-12 in T-helper cell development and its regulation by TGF-beta, IFN-gamma and IL-4. Chem. Immunol. 68:70-85[Medline]. |
| 46. | Shull, M. M., I. Ormsby, A. B. Kier, S. Pawlowski, R. J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin, et al. 1992. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:693-699[CrossRef][Medline]. |
| 47. |
Silva, J. S.,
D. R. Twardzik, and S. G. Reed.
1991.
Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta).
J Exp. Med.
174:539-545 |
| 48. | Spaccapelo, R., L. Romani, L. Tonnetti, E. Cenci, A. Mencacci, G. Del Sero, R. Tognellini, S. G. Reed, P. Puccetti, and F. Bistoni. 1995. TGF-beta is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans. J. Immunol. 155:1349-1360[Abstract]. |
| 49. | Tonnetti, L., R. Spaccapelo, E. Cenci, A. Mencacci, P. Puccetti, R. L. Coffman, F. Bistoni, and L. Romani. 1995. Interleukin-4 and -10 exacerbate candidiasis in mice. Eur. J. Immunol. 25:1559-1565[Medline]. |
| 50. | Ulloa, L., J. Doody, and J. Massague. 1999. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397:710-713[CrossRef][Medline]. |
| 51. |
Vodovotz, Y.,
C. Bogdan,
J. Paik,
Q. W. Xie, and C. Nathan.
1993.
Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta.
J. Exp. Med.
178:605-613 |
| 52. |
Wahl, S. M.,
J. B. Allen,
B. S. Weeks,
H. L. Wong, and P. E. Klotman.
1993.
Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes.
Proc. Natl. Acad. Sci. USA
90:4577-4581 |
| 53. | Wahl, S. M., I. M. Katona, B. M. Stadler, R. L. Wilder, W. E. Helsel, and L. M. Wahl. 1984. Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). II. Functional properties of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions. Cell. Immunol. 85:384-395[CrossRef][Medline]. |
| 54. | Walsh, T. J., S. Aoki, F. Mechinaud, J. Bacher, J. Lee, M. Rubin, and P. A. Pizzo. 1990. Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J. Infect. Dis. 161:755-760[Medline]. |
| 55. | Walsh, T. J., J. Bacher, and P. A. Pizzo. 1988. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab. Anim. Med. 38:467-471. |
| 56. | Walsh, T. J., P. O. Whitcomb, S. G. Revankar, and P. A. Pizzo. 1995. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 76:2357-2362[CrossRef][Medline]. |
| 57. | Welch, G. R., H. L. Wong, and S. M. Wahl. 1990. Selective induction of Fc gamma RIII on human monocytes by transforming growth factor-beta. J. Immunol. 144:3444-3448[Abstract]. |
| 58. | Williams, A. O., S. J. Chanock, and C. Flanders. 1995. TGF-beta isoforms in leprosy: immunohistochemical studies. Cell Vision 2:363-372. |
| 59. | Yang, X., J. J. Letterio, R. J. Lechleider, L. Chen, R. Hayman, H. Gu, A. B. Roberts, and C. Deng. 1999. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 18:1280-1291[CrossRef][Medline]. |
| 60. | Zhang, Y., and R. Derynck. 1999. Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell Biol. 9:274-279[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|